

DAFTAR PUSTAKA

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727–33.
2. World Health Organization. COVID-19 Weekly Epidemiological Update 22. *World Heal Organ [Internet]*. 2020;(December):1–3.
3. Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. *J Infect Public Health [Internet]*. 2020;13(9):1187–95.
4. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet [Internet]*. 2020;395(10236):1569–78.
5. Ghanbari R, Teimoori A, Sadeghi A, Mohamadkhani A, Rezasoltani S, Asadi E, et al. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. *Future Microbiol*. 2020;15(18):1747–58.
6. Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286. 2020;47(5):PP:342.
7. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. *Pedoman Tatalaksana Covid-19. third. Jakarta;2020*
8. Anderson M, Bach P, Baldwin M. Hospital Length of Stay for Patient with severe COVID-19 : Implications for Remdesivir' Value. *PharmacoEconomic*. 2020:129-31
9. Sreekanth Reddy O, Lai WF. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. *ChemBioChem*. 2020;1–11.
10. Guan W, Liang W, Zhao Y, Liang H, Cheng Z, Li Y et al. Comorbids and its Impact on 1590 patient With COVID-19 in China: A Nation Wide Analysis. *Eur Respi J* :2020;55, 1-14.
11. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. Vol. 39, *Journal of Heart and Lung Transplantation*. 2020. p. 405–7.
12. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. *Arch Pharm Res [Internet]*. 2021;44(1):99–116.
13. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun*. 2020;17:1-10.
14. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 70 [Internet]. WHO; 2020 [updated 2021 Feb 06; cited 2021 Feb 06].
15. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. *Pedoman Kesiapsiagaan Menghadapi Coronavirus Disease (COVID-19)*. 2 ed: Kementerian Kesehatan RI; 2020: 5-6
16. De Simone G, Mancusi C. COVID-19: timing is important. *Eur J Intern Med* 2020;77:134–
17. Perhimpunan Dokter Paru Indonesia. *Protokol Tatalaksana Pasien COVID-19*. Jakarta, 3 April 2020.

18. Acosta PE. Antiviral Agents (Nonretroviral). In: Brunton LL, Danfan RH, Knollmann BJ, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics 13th ed. New York: McGraw-Hill Company. 2018.p.1105-16
19. Sur M, Baker MB. Oseltamivir. [Updated 2019 Oct 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
20. Kongsadao S. Various Combination of Protease Inhibitors, Oseltamivir, favipiravir, and Chloroquin for treatment of COVID19: A Randomized control trial (THDMS-COVID19). March 2020. ClinicalTrial.gov: NCT04303299
21. Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea PLoS Med. 2018;13(3):1-36.
22. Tejaswi P, Devashish K, Prasad R. Pharmacological Effects of Favipiravir on Coronavirus: An Update. Biomedical & Pharmacology Journal, 2021. 14(2), p. 1087-95.
23. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control. Engineering. 2020.
24. Pharmaceuticals and Medical Devices Agency. Evaluation of Avigan Tablet 200 Mg.; 2019.
25. Gilead Sciences. Gilead announces approval of veclury® (remdesivir) in Japan for patients with severe COVID-19 [Internet]. 2020 [cited 2020 May 26].
26. Choy KT, Wong AYL, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res. 2020 Apr 3; 178 [Epub ahead of print]. PMID: 32251767
27. Gordon CJ, Tshesnokov EP, Woolner E, Perry JK, Feng JYm, Porter DP et al. Remdesivir is a direct-acting antiviral that inhibits RNA- dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020 Apr 13 [Epub ahead of print]. PMID: 32284326
28. Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Preprint. (not peer reviewed).
29. National Institutes of Health. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19 [Internet]. 2020 [cited 2020 May 26].
30. Azer.SA. COVID-19 : patofisiology, diagnosis, complication, investigonal therapy. Departement of Medical Education. 2020;1-8
31. Notoatmojo S. Metodologi Penelitian Kesehatan.PT Rineka Cipta . Jakarta; 2010;p 129.
32. Liu W, Zhou P, Chen K, Ye Z,Liu F, Li X. Efficacy and safety of antiviral treatment for COVID-19 from evidence in Studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.CMAJ.2020 July;p 734-44.

33. Zhou F, Yu T, Du RH. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62
34. He XW, Lai JS, Cheng J. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. *Chin J Cardiol* (2020-03-15) [2020-04-15]
35. Bai P, He W, Zhang XC. Analysis of clinical features of 58 patients with severe or critical 2019 novel coronavirus pneumonia. *Chin J Emerg Med* (2020-03-07) [2020-04-15]
36. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly*. 2020;2(8):10.
37. Brurberg K, Fretheim A. COVID-19: The relationship between age, comorbidity and disease severity—a rapid review. [COVID-19: Sammenheng mellom alder, komorbiditet og sykdomsalvorlighet – en hurtigoversikt. *Hurtigoversikt* 2020.] Oslo: Norwegian Institute of Public Health, 2020; 1-12.
38. Jin JM, Bai P, He W. Gender differences in patients with COVID-19: focus on severity and mortality, *Front. Public Health* 8 (2020) 152
39. M. Alkhouli, A. Nanjundappa, F. Annie, et al., Sex differences in case fatality rate of COVID-19: insights from a multinational registry, *Mayo Clin. Proc.* 95 (2020) 1613–20.
40. Li J, Wang L, Liu C, Wang Z, Lin Y, Dong X et al. Exploration of prognostic factors for critical COVID-19 patients using a nomogram model, *Scientific Reports* (2021) 11:8192.
41. Ya'qoub L, Elgendy I, Pepine CJ. Sex and gender differences in COVID-19: More to be learned!. *American Heart Journal Plus: Cardiology Research and Practice*.2021;3; 1-5.
42. Czapla, M.; Juárez-Vela, R.; Gea-Caballero, V.; Zieliński, S.; Zielińska, M. The Association between Nutritional Status and In Hospital Mortality of COVID-19 in Critically-Ill Patients in the ICU. *Nutrients* 2021, 13, 1-15.
43. Padilla IA, Moguel NC, Vargas AA, Llmazares SR. High nutritional risk using NUTRIC-Score is associated with worse outcomes in COVID-19 critically ill patients. *Nutr Hosp.* 2021 Jun 10;38(3):540-4.
44. Dana, R, Bannay, A, Bourst, P, Ziegler, C, Losser, M.-R, Gibot, S, et al. Obesity and Mortality in Critically Ill COVID-19 Patients with Respiratory Failure. *Int. J. Obes.* 2021, 45, 2028–37.
45. Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. *Mayo Clin. Proc.* 2020, 95, 1445–53
46. Wang J, Sato T, Sakuraba A. Worldwide Association of Lifestyle-Related Factors and COVID-19 Mortality. *Ann. Med.* 2021, 53, 1528–33
47. Pelosi P, Croci M, Ravagnan I, Vicardi P, Gattinoni L. Total Respiratory System, Lung, and Chest Wall Mechanics in Sedated-Paralyzed Postoperative Morbidly Obese Patients. *Chest* 1996, 109, 144–51

48. Qin W, Bai W, Liu K, Liu Y, Meng X, Zhang K, Zhang M. Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. *Human Gene Therapy*; 32, (5);310-5.
49. Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021. *Prev Chronic Dis* 2021;18:210123.
50. J. Yang, Y. Zheng, X. Gou et al. “Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis,” *International Journal of Infectious Diseases*, 2020 vol. 94, pp. 91–5.
51. Nassar M, Daoud A, Nso N, Medina L, Geurnathan V, Banghoo H, et al. Diabetes Mellitus and COVID-19: Review Article. 2021. *Diabetes Metab Syndr*; 15(6): 102268.
52. Barrera FJ, Shekhar S, Wurth R, Moreno-Pena PJ, Ponce OJ, Hajdenberg M, et al. Prevalence of diabetes and hypertension and their associated risks for poor outcomes in Covid-19 patients. *J Endocr Soc.* (2020) 4:bvaa102.
53. Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). *JAMA Netw Open.* 2020;3(5): e2010478
54. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID19. *J Thromb Haemost.* 2020;18(8):1995-2002.
55. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med.* 2020;46(6):1089–98.
56. Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S et al. COVID-19 and Hypercoagulopathy: A Review. *Clinical and Applied Thrombosis/Hemostasis.* 2020, Vol 26: 1-9
57. Feng, G., Zheng, K. I., Yan, Q. Q., Rios, R. S., Targher, G., Byrne, C. D., et al. (2020). COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. *J. Clin. Transl Hepatol.* 8, 18–24.
58. Morgan, K., Samuel, K., Vandeputte, M., Hayes, P. C., and Plevris, J. N. (2020). SARS-CoV-2 Infection and the Liver. *Pathogens* 9 (6), 430
59. Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Xia, Z., et al. (2020). COVID-19 in a Designated Infectious Diseases Hospital outside Hubei Province, China: *Allergy*. 2020; p 1-8
60. Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., Yan, Y. Q., et al. (2020). Clinical Characteristics of 140 Patients Infected with SARS-CoV-2 in Wuhan, China. *Allergy* 75 (7), 1730–41
61. Piano, S., Dalbeni, A., Vettore, E., Benfaremo, D., Mattioli, M., Gambino, C. G., et al. (2020). Abnormal Liver Function Tests Predict Transfer to Intensive Care Unit and Death in COVID-19. *Liver Int.* 40 (10), 2394–40

62. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *New Engl. J. Med.* 2020; 383; p 993-7
63. Davies, M., Osborne, V., Lane, S., Roy, D., Dhanda, S., Evans, A., et al. (2020). Remdesivir in Treatment of COVID-19: A Systematic Benefit Risk Assessment. *Drug Saf.* 43 (7), 645–56
64. Ohl ME, Miller D, Lund B. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. *JAMA Netw Open.* 2021;4(7):e2114741.
65. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He L, Lu X, Zhao Q, Liang T, Qiu Y (2021) Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. *Eur J Pharm Sci* 157:105631
66. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Karim A, Murthy et al; WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity Trial results. *N Engl J Med.* 2021;384(6):497-511.
67. Dodaran M, Ghanei M, Bagheri M, Qasvini A, Vahedi E, Saadat S et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *International Immunopharmacology.* 2021; 95; 107522.



